Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy

International Braz J Urol

Volumn 36, Issue 6, 2010, Pages 700-707

  Coward, Robert M ^a   Simhan, Jay ^a   Carson, Culley C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Continental population groups; Hypogonadism; Prostate specific antigen; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; ETHNOLOGY; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; RETROSPECTIVE STUDIES; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251549534     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382010000600008     Document Type: Article

References (27)

1. American Association of Clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 2002; 8: 439-56.
2. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al.: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006; 91: 1995-2010.
3. Erratum in: J Clin Endocrinol Metab. 2006; 91: 2688.
4. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al.: Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004; 89: 5920-6.
5. Ellis L, Nyborg H: Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids. 1992; 57: 72-5.
6. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K: Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev. 2002; 11: 1041-7.
7. Winters SJ, Brufsky A, Weissfeld J, Trump DL, Dyky MA, Hadeed V: Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism. 2001; 50: 1242-7.
8. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, et al.: Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995; 4: 735-41.
9. Abdelrahaman E, Raghavan S, Baker L, Weinrich M, Winters SJ: Racial difference in circulating sex hormone-binding globulin levels in prepubertal boys. Metabolism. 2005; 54: 91-6.
10. Asbell SO, Raimane KC, Montesano AT, Zeitzer KL, Asbell MD, Vijayakumar S: Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients. J Natl Med Assoc. 2000; 92: 445-9.
11. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E: Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000; 92: 2009-17.
12. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986; 76: 45-8.
13. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, et al.: Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007; 92: 2519-25.
14. Litman HJ, Bhasin S, Link CL, Araujo AB, McKinlay JB: Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab. 2006; 91: 4326-34.
15. Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, et al.: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995; 274: 1277-81.
16. Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, et al.: Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997; 89: 134-8.
17. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW: Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996; 335: 304-10.
18. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, Aronson WJ, et al.: Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007; 69: 1138-42.
19. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J: Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999; 53: 581-9.
20. Irvine RA, Yu MC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995; 55: 1937-40.
21. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR: CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther. 2000; 68: 82-91.
22. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003; 24: 299-311.
23. Rhoden EL, Morgentaler A: Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 2006; 18: 201-5.
24. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004; 89: 2085-98.
25. El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA: Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med. 2005; 2: 235-40.
26. Coward RM, Simhan J, Carson CC 3rd: Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int. 2009; 103: 1179-83.
27. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R: Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005; 174: 827-34.